TITLE

Effectiveness of Bevantolol in the Treatment of Angina -- A Placebo-Controlled Study

AUTHOR(S)
John Farnham, D.
PUB. DATE
March 1986
SOURCE
Angiology;Mar1986 Part 2, Vol. 37 Issue 3, p226
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The antianginal efficacy and safety of bevantolol was compared with placebo in 107 patients with angina pectoris of effort. The median frequency of angina attacks in these patients was 6 per week. Following a 6-week placebo-baseline phase, the patients were randomly assigned to groups receiving either 150 or 300 mg/day bevantolol (75 or 150 mg b.i.d.) or placebo for 6 weeks of doubleblind treatment. During exercise tolerance testing at 2 hours postdose, the higher dose of bevantolol produced a marked increase in total work performed. Double product (HR × Systolic BP) at maximum common work load decreased significantly (p < 0.001) in both bevantolol groups compared with the placebo group. In patients receiving 300 mg/day bevantolol, the proportion who stopped exercising because of angina or S-T depression decreased from 97% to 65%; the frequency of angina attacks decreased by one-half or more in 77% of those with 3 or more attacks per week; and 90% had an improvement in capacity to perform usual daily and occupational activities. A significant therapeutic effect was still present 12 hours postdose. Bevantolol was safe; fewer adverse reactions occurred in either drug group than in the placebo group. Bevantolol appeared to be an effective, well-tolerated drug in the management of angina pectoris.
ACCESSION #
16365105

 

Related Articles

  • Assessment of Anti-Ischemic and Antianginal Effect at Trough Plasma Concentration and Safety of Trimetazidine MR 35mg in Patients with Stable Angina Pectoris: A Multicenter, Double-Blind, Placebo-Controlled Study. Philippe Sellier; Jean-Paul Broustet // American Journal of Cardiovascular Drugs;2003, Vol. 3 Issue 5, p361 

    Objective: The study aimed to assess, at trough plasma concentration, the anti-ischemic and antianginal efficacy and tolerability of trimetazidine modified release (MR) 35mg taken twice daily by patients with stable angina pectoris. Design: This multicenter, randomized, double-blind,...

  • Angeze.  // Royal Society of Medicine: Medicines;2002, p61 

    The article provides information on Angeze, a proprietary, non-prescription preparation of the drug isosorbide mononitrate. It can be used as an anti-angina drug, and is available as tablets.

  • Angina Pectoris.  // Encyclopedic Reference of Molecular Pharmacology;2004, p38 

    The article presents an encyclopedia entry for angina pectoris. It refers to a clinical syndrome caused by transient myocardial ischemia. Patients suffer from a squeezing substernal discomfort and the pain may radiate to the left shoulder and to other regions of the body. They may also suffer...

  • variant angina. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p782 

    An encyclopedia entry for "variant angina" is presented. It refers to a medical condition in which chest pain occurs when at rest, often during sleep. Variant angina, which is a form of angina pectoris, also known as Prinzmetal's angina, is accompanied by breathlessness and palpitations. The...

  • Ranolazine: A Review of its Use in Chronic Stable Angina Pectoris. Siddiqui, M. Asif A.; Keam, Susan J. // Drugs;2006, Vol. 66 Issue 5, p693 

    Ranolazine (Ranexaâ„¢), a piperazine derivative, is a new antianginal agent approved for the treatment of chronic stable angina pectoris for use as combination therapy when angina is not adequately controlled with other antianginal agents. While the exact mechanism of action of ranolazine is...

  • Ludwig's Angina. Heavey, Jon; Gupta, Naren // New England Journal of Medicine;10/2/2008, Vol. 359 Issue 14, p1501 

    The article focuses on the case of a healthy 58 year old man who was evaluated and treated for a toothache which had lasted for two days. A discussion is presented of the man's return to physicians within twenty four hours of being treated, and of symptoms of severe swelling in his neck, sore...

  • Chest pain -- is it angina? Browne, Lisa // World of Irish Nursing;Feb2004, Vol. 12 Issue 2, p35 

    Presents a continuing education module on chest pain and angina pectoris. Symptoms of chest pain; Cause of angina pectoris; Distinction between cardiac and non-cardiac symptoms; Assessment that patients with suspected cardiac chest pain should receive; Treatment strategies in the management of...

  • Pay Heed to Pain.  // Prevention India;Apr2015, p1 

    The article focuses on angina or chest discomfort/chest pain, which is a major symptom of heart disease, and how to distinguish it from other chest pains. It occurs when the heart muscle does not get enough oxygen due to critical narrowing of coronary arteries . Classic angina is manifested with...

  • Scoring system to manage angina. Fuat, Ahmet // GP: General Practitioner;6/9/2006, p23 

    The article reports on how to manage angina. Angina is a common problem in primary care. While most patients with stable angina have low mortality, research suggests that the five-year risk of death, disabling stroke or myocardial infarction ranges from 4 percent to 35 percent, depending on...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics